Literature DB >> 14612932

Transcriptional regulation of the beta1C integrin splice variant in human prostate adenocarcinoma.

Loredana Moro1, Margherita Greco, Pasquale Ditonno, Michele Battaglia, Ersilia Marra, Elda Perlino.   

Abstract

Members of the integrin family of cell adhesion receptors influence several important aspects of cancer cell behaviour, including motility and invasiveness, cell growth and cell survival. beta1C integrin, an alternatively spliced variant of the human beta1 integrin, has been shown to inhibit cell proliferation. We have previously demonstrated that beta1C integrin mRNA and protein are present in normal prostate and are down-regulated in prostate adenocarcinoma. To explore some of the molecular mechanisms regulating beta1C integrin gene expression, we have analysed the transcriptional activity of the beta1 integrin gene in neoplastic and normal human prostate tissue. Run-on analysis demonstrates that the transcription rate of the beta1 integrin gene is significantly reduced in prostate cancer specimens compared to normal prostate, thus accounting for the reduction in mRNA levels of the beta1 integrin variants. Moreover, the decrease in transcriptional activity of the beta1 integrin gene directly correlates to the reduction of beta1C integrin steady-state mRNA levels (r=0.78).

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14612932

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  2 in total

1.  Mycophenolate mofetil modulates adhesion receptors of the beta1 integrin family on tumor cells: impact on tumor recurrence and malignancy.

Authors:  Tobias Engl; Jasmina Makarević; Borna Relja; Iyad Natsheh; Iris Müller; Wolf-Dietrich Beecken; Dietger Jonas; Roman A Blaheta
Journal:  BMC Cancer       Date:  2005-01-11       Impact factor: 4.430

2.  Fyn/heterogeneous nuclear ribonucleoprotein E1 signaling regulates pancreatic cancer metastasis by affecting the alternative splicing of integrin β1.

Authors:  Peng Jiang; Zhonghu Li; Feng Tian; Xiaowu Li; Jin Yang
Journal:  Int J Oncol       Date:  2017-05-24       Impact factor: 5.650

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.